HypertensionConcentRatioNCT05114291
From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys
An observational study of Hypertension, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Hypertension is a public health concern and affects nearly a third of the French population. It can be complicated by visceral impact (including brain, heart and kidney complications) as well as on vessels especially large arteries, responsible for arterial stiffening. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- Explorations are planned as part of the one-day hospitalization
- How many people
- 72 participants
- Where
- 1 siteFrance
- Study dates
- 10 Dec 2021to 7 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study concerns patients with hypertension who are addressed to a one-day hospitalization in order to realize standardized examinations (must include hormonal analyses : renin and aldosterone)
Who may be able to join
- Adults patients
- Day hospitalization for a check-up in the context of arterial hypertension with suspicion of secondary origin including a dosage of renin and plasma aldosterone
- Non-opposition to the study
Who cannot join
- Cardiac arrythmia
- Patient under AME (state medical assistance)
- Treatments interfering with uninterrupted hormonal dosages before day hospitalization
- Absence of B-blockers, converting enzyme inhibitor and sartans in the 15 days preceding the dosages
- Absence of antialdosterone, and amiloride in the 6 weeks preceding the dosages
- Absence of loop diuretics or diuretics in the 7 days preceding the dosages
Trial locations and contacts
1 site in 1 country.
France1 site
Centre Interdisciplinaire de Thérapeutique et d'Education APHP- Hôtel Dieu Hospital
Paris, IDF, 75004
About this study
Hypertension is a public health concern and affects nearly a third of the French population. It can be complicated by visceral impact (including brain, heart and kidney complications) as well as on vessels especially large arteries, responsible for arterial stiffening. There are close interactions between heart and kidneys, as well as between large arteries and micro-vessels. These relationships also involve the water and salt balance and its regulatory mechanisms. Urinary concentration abilities are closely linked to the renal medullary blood flow, which in itself depends on the integrity of renal micro vessels, thus influencing the water and salt balance. Few previous studies evaluated the interconnections between renal urinary concentration abilities and blood pressure. A previous-one reported a positive relation between pulse pressure and urinary concentration in men, suggesting that subjects with higher urinary osmolarity could present a higher cardiovascular risk. Carotid-femoral pulse wave velocity represents the gold standard for non-invasive arterial stiffness assessment and constitutes an arteriosclerosis infra-clinical marker recommended by the European Society of Cardiology- European Society of Hypertension. It is considered as an independent predictor for global and cardiovascular mortality, coronary heart disease and fatal stroke among patients with hypertension, diabetes or end stage kidney disease. The purpose of this study is to evaluate the relations between fasting urinary osmolarity and arterial stiffness assessed by carotid-femoral pulse wave velocity (CF-PWV) among patients with hypertension.
Read the detailed description
- Hypertension
- Hypertension, kidneys et urinary sodium excretion Kidneys are heavily involved in blood pressure regulation in particular through water and salt balance control, and their impact on vasomotor tone through the renin-angiotensin aldosterone system (RAAS), prostaglandins or atrial natriuretic factor (FAN) actions. They take a central place in blood pressure regulation and indirectly in arterial stiffening. Daily urinary sodium excretion represents a major determinant of blood pressure. It is defined as the product of urinary sodium concentration and urinary output. In a steady state, it equals sodium intake. When kidneys are unable to excrete sodium, blood volume and blood pressure increase. The result is an adaptive decrease in sodium reabsorption (called "pressure natriuresis"), in order to restore the sodium balance. "Salt sensitivity" has been defined as a significant increase in blood pressure associated with the increase sodium intake. It has been associated with age, ethnicity, obesity, metabolic syndrome, and chronic kidney disease (CKD). Chronic kidney disease is frequently associated with salt and fluid retention, which promote hypertension and increase cardiovascular risk. Among dialysis patients, fluid overload has been widely described as an independent mortality risk factor. Recently, Faucon et al. reported in the nephroTEST cohort of CKD patients not yet on dialysis that the measured extra cellular volume (ECV) was an independent risk factor for mortality but also for CKD progression to the end stage of kidney disease. Reduced sodium excretion abilities associated with CKD progression lead to fluid overload and cardiac consequences. The increase of left ventricular preload promotes diastolic dysfunction. In parallel, the prolonged increase of left ventricular afterload promotes left ventricular hypertrophy. Other CKD associated factors could also contribute to left ventricular hypertrophy such as the increased arterial stiffness, and CKD-mineral and bone disorders including the raise of FGF-23.
- Nephron, water and salt balance regulation, and outside of the glomerulus The nephron represents the kidney functional unit. It plays a major role in water and salt balance control. "Kidney function" assessment is often reduced to its glomerular functions, including glomerular filtration rate (GFR) and albuminuria level. The other segments of the nephron are however largely involved in this balance control. Their function can be altered even without glomerular dysfunction and therefore without renal insufficiency. Thus, tubular segments, peritubular capillaries and the interstitial space can also be altered in some kidney diseases. These structures, and more particularly the ascending limb of the loop of Henle, the peritubular micro-vessels and the collecting duct, are involved in the corticopapillary gradient creation and maintenance. This gradient is essential for the urine concentrating mechanism. Tubular damages assessed on renal pathology would also be more correlated to impaired urine concentration and acidification than to glomeruli involvement. Fasting urinary osmolarity is a simple, non-invasive marker for assessing urinary concentration abilities. It is yet poorly studied in clinical research. At same level of GFR, its level would be associated with tubular dysfunctions and peritubular vascular lesions, namely with medullary functions. Fasting urinary osmolarity has also been associated with GFR decline and progression of CKD to end stage kidney disease. On the other hand, some of the tubular segments constitute direct targets of systemic hormonal regulation. Aldosterone thus promotes sodium retention and potassium excretion through the activation of mineralocorticoid receptors located on distal tubular cells and the involvement of ENaC and ROMK channels.
- Hypertension and urinary concentration Perrucca et al. suggested that urinary concentration and its regulatory hormone, antidiuretic hormone (ADH), may contribute to cardiovascular disease susceptibility. ADH binding to its V2R receptor promotes distal reabsorption of free water and thus favors urinary concentration. This hormone has thus an action through kidneys promoting urinary concentration through free water reabsorption, but also a vascular effect leading to vasoconstriction. Hypertension has been associated with increased plasma ADH levels. Zhang et al. thus reported in a cohort of 534 middle-aged subjects, the significant association between plasma ADH levels and blood pressure levels as well as with hypertension, especially in patients with low plasma renin activity. The antidiuretic hormone would also be at higher levels in men than in women, as well as in African American subjects compared to Caucasians, likewise hypertension is also more frequent in these two populations. Furthermore, Bankir et al. described in a retrospective cohort of 141 healthy subjects of 18 to 40 years old that black individuals presented significantly higher urine concentration and lower urinary volume than white individuals. In addition, a significant and positive relationship between urinary concentration levels and pulse pressure was found among men. This association was more marked among black individuals compared to white individuals. Since pulse pressure is currently considered as an independent risk factor for cardiovascular disease, associated with both cardiovascular morbidity (increased incidence of myocardial infarction or congestive heart failure) and cardiovascular mortality from coronary artery disease, an association between urinary concentration abilities and cardiovascular risk could be considered. In addition, urine dilution by increasing water intake is one of the main objective in the management of lithiasis patients. The increase of urinary concentration is indeed associated with an increased risk of crystallization and therefore an increased risk of kidney stones recurrence. Lithiasis patients have also been described as a population with an increased cardiovascular risk. These additional elements support the hypothesis of a potential association between urinary concentration and cardiovascular risk.
- Arterial stiffness
- Hypertension, arteriosclerosis and evaluation Arteriosclerosis represents an arterial degeneration process associated with physiological aging but much more marked in some pathological circumstances such as hypertension, diabetes or chronic kidney disease. The arterial wall involvement concerns the media of large arteries, unlike atherosclerosis in which the involvement initially involves the intima, resulting in an accelerated stiffening of the vascular tree. Large arteries stiffening can induce myocardial hypertrophy, favors heart failure, arrhythmias and even myocardial ischemia. Carotid-femoral pulse wave velocity enables non-invasive assessment of central arterial stiffness. It currently represents the gold standard for non-invasive arterial stiffness measurements and constitutes an arteriosclerosis infra-clinical marker recommended by the European Society of Cardiology- European Society of Hypertension. In practice, it corresponds to the velocity at which the pulse wave propagates over a specific arterial segment. The pulse wave travels slowly through flexible and elastic arteries, and rapidly through rigid arteries. CF-PWV measurement requires an automated software. It is a simple, non-invasive, validated, robust, reproducible and accessible procedure in clinical practice.
- Arterial stiffness and cardiovascular risk CF-PWV thus enables us to detect large arteries damages at an infra-clinical stage and to identify populations at high cardiovascular risk. It has been described as an independent predictor for global and cardiovascular mortality, coronary heart disease and fatal stroke in many populations: in the general population, in elderly patients, in patients with diabetes, with hypertension, in CKD-patients, patients with end-stage kidney disease, and also in renal transplant recipients. Aortic stiffness has been shown to be predictive of cardiovascular events, independently and beyond traditional risk factors and the Framingham score.
- Arterial stiffness and fluid overload Fluid overload can also contribute to structural and functional alterations in large arteries and therefore promote arterial stiffness. The increase in venous pressure induced by sodium overload initiates a vicious circle. The result is an increase in renal interstitial pressure, which disrupts renal blood flow, and promotes further retention. Plasma volume expands, increasing venous pressure further. The associated increase in filling pressures could thus promote structural and functional alteration of large arteries. Furthermore, the diastolic blood pressure decrease induce a reduction in coronary perfusion pressure, which contributes to myocardial ischemia. In case of heart failure, sodium retention is associated with a defective arterial filling. Urinary sodium excretion decreases while sodium and fluid overload increases.
- Micro- and macro-vessels relationships Safar et al. previously reported the links between macro- and micro-vessels evidenced by mouse models of hypertension and human studies. Indeed, pulse pressure increase associated with arterial compliance disturbances promotes impaired microcirculation, particularly in kidneys. An alteration of the extracellular matrix could involve both vascular smooth muscle cells (VSMCs) and renal cells. Several underlying physiopathological mechanisms have been suggested, involving notably the water and salt balance and the hormonal systemic regulatory mechanisms including the renin-angiotensin-aldosterone system. Urinary concentration abilities are closely linked to the renal medullary blood flow which itself depends on the renal microcirculation integrity.
- Studied-population
This study focus on patients with severe/resistant hypertension and/or with suspicion of secondary hypertension, who are addressed in a one-day hospitalization to benefit from standardized examinations including hormonal analyses (renin - aldosterone ± plasma cortisol). These hypertensive patients present an increased cardiovascular risk. The CF-PWV measure enables aortic stiffness assessment. It constitutes an arteriosclerosis infra-clinical marker recommended by the European Society of Cardiology- European Society of Hypertension.
- Conditions
- Hypertension
- Being tested
- Explorations are planned as part of the one-day hospitalization
- Keywords
- Hypertension, Aortic stiffness, Fasting urinary osmolarity, Cardiovascular risk
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Explorations are planned as part of the one-day hospitalizationOther
- Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition).
- Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity)
- Standardized blood pressure measurement :
- After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : "un-attended", then "attended"
- Hemodynamic parameters :
- Sphygmocor® : measure of the central blood pressure and pulse wave velocity
- MESI® tool : measure of the Systolic Pressure Index (PSI or IPS)
- pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device
- Others : if indicated (echocardiography, ABPM)
What is being measured
The primary outcome is the main question the study is designed to answer.
CF-PWV
Carotid-femoral pulse wave velocity
Measured: Inclusion
Secondary outcomes (5)
PRA
Plasma renin activity
Measured: Inclusion
Nocturnal dipping percentage of systolic blood pressure
Nocturnal dipping percentage of systolic blood pressure
Measured: Inclusion
Smoking status
Declared smoking status
Measured: Inclusion
Ankle-brachial pressure index (ABPI)
Ankle-brachial pressure index (ABPI)
Measured: Inclusion
Primary hyperaldosteronism
Primary hyperaldosteronism diagnosis
Measured: Inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2021
- Study start10 Dec 2021
- Primary completion7 Jun 2023
- Study completion7 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 72 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- Responsible party
- Sponsor
- Investigators
- Lynda CHEDDANI, MD, Study director, Assistance Publique - Hôpitaux de Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05114291
- Sponsor's protocol ID
- APHP210934
- Other IDs
- 2021-A01291-40
- Acronym
- ConcentRatio
- Status last verified
- Sep 2025
- First submitted
- 22 Oct 2021
- Last updated
- 15 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys
- ClinicalTrials.gov ID
- NCT05114291
- Acronym / sponsor ID
- ConcentRatio / APHP210934
- Conditions
- Hypertension
- Keywords
- Hypertension, Aortic stiffness, Fasting urinary osmolarity, Cardiovascular risk
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 72 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- Study start
- 10 Dec 2021 (actual)
- Primary completion
- 7 Jun 2023 (actual)
- Study completion
- 7 Jul 2023 (actual)
- First posted
- 9 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hypertension is a public health concern and affects nearly a third of the French population. It can be complicated by visceral impact (including brain, heart and kidney complications) as well as on vessels especially large arteries, responsible for arterial stiffening. There are close interactions between heart and kidneys, as well as between large arteries and micro-vessels. These relationships also involve the water and salt balance and its regulatory mechanisms. Urinary concentration abilities are closely linked to the renal medullary blood flow, which in itself depends on the integrity of renal micro vessels, thus influencing the water and salt balance. Few previous studies evaluated the interconnections between renal urinary concentration abilities and blood pressure. A previous-one reported a positive relation between pulse pressure and urinary concentration in men, suggesting that subjects with higher urinary osmolarity could present a higher cardiovascular risk. Carotid-femoral pulse wave velocity represents the gold standard for non-invasive arterial stiffness assessment and constitutes an arteriosclerosis infra-clinical marker recommended by the European Society of Cardiology- European Society of Hypertension. It is considered as an independent predictor for global and cardiovascular mortality, coronary heart disease and fatal stroke among patients with hypertension, diabetes or end stage kidney disease. The purpose of this study is to evaluate the relations between fasting urinary osmolarity and arterial stiffness assessed by carotid-femoral pulse wave velocity (CF-PWV) among patients with hypertension.
Detailed description
- Hypertension
- Hypertension, kidneys et urinary sodium excretion Kidneys are heavily involved in blood pressure regulation in particular through water and salt balance control, and their impact on vasomotor tone through the renin-angiotensin aldosterone system (RAAS), prostaglandins or atrial natriuretic factor (FAN) actions. They take a central place in blood pressure regulation and indirectly in arterial stiffening. Daily urinary sodium excretion represents a major determinant of blood pressure. It is defined as the product of urinary sodium concentration and urinary output. In a steady state, it equals sodium intake. When kidneys are unable to excrete sodium, blood volume and blood pressure increase. The result is an adaptive decrease in sodium reabsorption (called "pressure natriuresis"), in order to restore the sodium balance. "Salt sensitivity" has been defined as a significant increase in blood pressure associated with the increase sodium intake. It has been associated with age, ethnicity, obesity, metabolic syndrome, and chronic kidney disease (CKD). Chronic kidney disease is frequently associated with salt and fluid retention, which promote hypertension and increase cardiovascular risk. Among dialysis patients, fluid overload has been widely described as an independent mortality risk factor. Recently, Faucon et al. reported in the nephroTEST cohort of CKD patients not yet on dialysis that the measured extra cellular volume (ECV) was an independent risk factor for mortality but also for CKD progression to the end stage of kidney disease. Reduced sodium excretion abilities associated with CKD progression lead to fluid overload and cardiac consequences. The increase of left ventricular preload promotes diastolic dysfunction. In parallel, the prolonged increase of left ventricular afterload promotes left ventricular hypertrophy. Other CKD associated factors could also contribute to left ventricular hypertrophy such as the increased arterial stiffness, and CKD-mineral and bone disorders including the raise of FGF-23.
- Nephron, water and salt balance regulation, and outside of the glomerulus The nephron represents the kidney functional unit. It plays a major role in water and salt balance control. "Kidney function" assessment is often reduced to its glomerular functions, including glomerular filtration rate (GFR) and albuminuria level. The other segments of the nephron are however largely involved in this balance control. Their function can be altered even without glomerular dysfunction and therefore without renal insufficiency. Thus, tubular segments, peritubular capillaries and the interstitial space can also be altered in some kidney diseases. These structures, and more particularly the ascending limb of the loop of Henle, the peritubular micro-vessels and the collecting duct, are involved in the corticopapillary gradient creation and maintenance. This gradient is essential for the urine concentrating mechanism. Tubular damages assessed on renal pathology would also be more correlated to impaired urine concentration and acidification than to glomeruli involvement. Fasting urinary osmolarity is a simple, non-invasive marker for assessing urinary concentration abilities. It is yet poorly studied in clinical research. At same level of GFR, its level would be associated with tubular dysfunctions and peritubular vascular lesions, namely with medullary functions. Fasting urinary osmolarity has also been associated with GFR decline and progression of CKD to end stage kidney disease. On the other hand, some of the tubular segments constitute direct targets of systemic hormonal regulation. Aldosterone thus promotes sodium retention and potassium excretion through the activation of mineralocorticoid receptors located on distal tubular cells and the involvement of ENaC and ROMK channels.
- Hypertension and urinary concentration Perrucca et al. suggested that urinary concentration and its regulatory hormone, antidiuretic hormone (ADH), may contribute to cardiovascular disease susceptibility. ADH binding to its V2R receptor promotes distal reabsorption of free water and thus favors urinary concentration. This hormone has thus an action through kidneys promoting urinary concentration through free water reabsorption, but also a vascular effect leading to vasoconstriction. Hypertension has been associated with increased plasma ADH levels. Zhang et al. thus reported in a cohort of 534 middle-aged subjects, the significant association between plasma ADH levels and blood pressure levels as well as with hypertension, especially in patients with low plasma renin activity. The antidiuretic hormone would also be at higher levels in men than in women, as well as in African American subjects compared to Caucasians, likewise hypertension is also more frequent in these two populations. Furthermore, Bankir et al. described in a retrospective cohort of 141 healthy subjects of 18 to 40 years old that black individuals presented significantly higher urine concentration and lower urinary volume than white individuals. In addition, a significant and positive relationship between urinary concentration levels and pulse pressure was found among men. This association was more marked among black individuals compared to white individuals. Since pulse pressure is currently considered as an independent risk factor for cardiovascular disease, associated with both cardiovascular morbidity (increased incidence of myocardial infarction or congestive heart failure) and cardiovascular mortality from coronary artery disease, an association between urinary concentration abilities and cardiovascular risk could be considered. In addition, urine dilution by increasing water intake is one of the main objective in the management of lithiasis patients. The increase of urinary concentration is indeed associated with an increased risk of crystallization and therefore an increased risk of kidney stones recurrence. Lithiasis patients have also been described as a population with an increased cardiovascular risk. These additional elements support the hypothesis of a potential association between urinary concentration and cardiovascular risk.
- Arterial stiffness
- Hypertension, arteriosclerosis and evaluation Arteriosclerosis represents an arterial degeneration process associated with physiological aging but much more marked in some pathological circumstances such as hypertension, diabetes or chronic kidney disease. The arterial wall involvement concerns the media of large arteries, unlike atherosclerosis in which the involvement initially involves the intima, resulting in an accelerated stiffening of the vascular tree. Large arteries stiffening can induce myocardial hypertrophy, favors heart failure, arrhythmias and even myocardial ischemia. Carotid-femoral pulse wave velocity enables non-invasive assessment of central arterial stiffness. It currently represents the gold standard for non-invasive arterial stiffness measurements and constitutes an arteriosclerosis infra-clinical marker recommended by the European Society of Cardiology- European Society of Hypertension. In practice, it corresponds to the velocity at which the pulse wave propagates over a specific arterial segment. The pulse wave travels slowly through flexible and elastic arteries, and rapidly through rigid arteries. CF-PWV measurement requires an automated software. It is a simple, non-invasive, validated, robust, reproducible and accessible procedure in clinical practice.
- Arterial stiffness and cardiovascular risk CF-PWV thus enables us to detect large arteries damages at an infra-clinical stage and to identify populations at high cardiovascular risk. It has been described as an independent predictor for global and cardiovascular mortality, coronary heart disease and fatal stroke in many populations: in the general population, in elderly patients, in patients with diabetes, with hypertension, in CKD-patients, patients with end-stage kidney disease, and also in renal transplant recipients. Aortic stiffness has been shown to be predictive of cardiovascular events, independently and beyond traditional risk factors and the Framingham score.
- Arterial stiffness and fluid overload Fluid overload can also contribute to structural and functional alterations in large arteries and therefore promote arterial stiffness. The increase in venous pressure induced by sodium overload initiates a vicious circle. The result is an increase in renal interstitial pressure, which disrupts renal blood flow, and promotes further retention. Plasma volume expands, increasing venous pressure further. The associated increase in filling pressures could thus promote structural and functional alteration of large arteries. Furthermore, the diastolic blood pressure decrease induce a reduction in coronary perfusion pressure, which contributes to myocardial ischemia. In case of heart failure, sodium retention is associated with a defective arterial filling. Urinary sodium excretion decreases while sodium and fluid overload increases.
- Micro- and macro-vessels relationships Safar et al. previously reported the links between macro- and micro-vessels evidenced by mouse models of hypertension and human studies. Indeed, pulse pressure increase associated with arterial compliance disturbances promotes impaired microcirculation, particularly in kidneys. An alteration of the extracellular matrix could involve both vascular smooth muscle cells (VSMCs) and renal cells. Several underlying physiopathological mechanisms have been suggested, involving notably the water and salt balance and the hormonal systemic regulatory mechanisms including the renin-angiotensin-aldosterone system. Urinary concentration abilities are closely linked to the renal medullary blood flow which itself depends on the renal microcirculation integrity.
- Studied-population
This study focus on patients with severe/resistant hypertension and/or with suspicion of secondary hypertension, who are addressed in a one-day hospitalization to benefit from standardized examinations including hormonal analyses (renin - aldosterone ± plasma cortisol). These hypertensive patients present an increased cardiovascular risk. The CF-PWV measure enables aortic stiffness assessment. It constitutes an arteriosclerosis infra-clinical marker recommended by the European Society of Cardiology- European Society of Hypertension.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study concerns patients with hypertension who are addressed to a one-day hospitalization in order to realize standardized examinations (must include hormonal analyses : renin and aldosterone)
Key inclusion criteria (3 listed)
- Adults patients
- Day hospitalization for a check-up in the context of arterial hypertension with suspicion of secondary origin including a dosage of renin and plasma aldosterone
- Non-opposition to the study
Key exclusion criteria (6 listed)
- Cardiac arrythmia
- Patient under AME (state medical assistance)
- Treatments interfering with uninterrupted hormonal dosages before day hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Explorations are planned as part of the one-day hospitalization* Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition). * Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity) * Standardized blood pressure measurement : * After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : "un-attended", then "attended" * Hemodynamic parameters : * Sphygmocor® : measure of the central blood pressure and pulse wave velocity * MESI® tool : measure of the Systolic Pressure Index (PSI or IPS) * pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device * Others : if indicated (echocardiography, ABPM) | Other | – |
Primary outcome
CF-PWV
Time frame: Inclusion
Carotid-femoral pulse wave velocity
5 secondary outcomes
PRA
Time frame: Inclusion
Nocturnal dipping percentage of systolic blood pressure
Time frame: Inclusion
Smoking status
Time frame: Inclusion
Ankle-brachial pressure index (ABPI)
Time frame: Inclusion
Primary hyperaldosteronism
Time frame: Inclusion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lynda CHEDDANI, MD study director
Assistance Publique - Hôpitaux de Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CF-PWV (time frame: Inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.